GlassScriptPhysician profile
Jeremy Schmidt
NPI 1184892622
$132,478.51
in general payments reported to CMS, 2019-2025
62 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24K · 2022: $30K · 2023: $34K · 2024: $21K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Travel and Lodging: $15K · Food and Beverage: $10K · Consulting Fee: $1,095 · Gift: $59.40 · Education: $39.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,510.13 |
| Travel and Lodging | $15,395.31 |
| Food and Beverage | $10,305.54 |
| Consulting Fee | $1,095.00 |
| Gift | $59.40 |
| Education | $39.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $73,046.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $40,092.61 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Mannkind Corporation | $4,955.80 | 2022-2025 | V-Go, Afrezza |
| Abbott Laboratories | $2,720.07 | 2021-2025 | Freestyle Libre 3 |
| Zealand Pharma US, INC. | $2,337.79 | 2021-2022 | |
| Dexcom, INC. | $827.80 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $737.68 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $700.76 | 2021-2025 | Jardiance, Synjardy |
| Amgen INC. | $691.68 | 2021-2025 | Evenity, Tepezza, Enbrel |
| Astrazeneca Pharmaceuticals LP | $663.27 | 2021-2022 | |
| Corcept Therapeutics | $651.52 | 2021-2025 | Korlym |
| Medtronic, INC. | $371.66 | 2021-2025 | Linq II, Minimed 780g |
| Amneal Pharmaceuticals LLC | $320.46 | 2021-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $290.66 | 2021-2024 | |
| Amarin Pharma, INC. | $282.14 | 2021-2022 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $275.92 | 2021-2025 | Nexletol |
| Antares Pharma, INC. | $206.18 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Sk Life Science, INC. | $194.28 | 2023 | |
| Insulet Corporation | $188.62 | 2021-2025 | Omnipod |
| Madrigal Pharmaceuticals | $185.34 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $179.44 | 2023-2025 | Isturisa, Signifor Lar |
| Beta Bionics, INC. | $172.89 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Averitas Pharma INC. | $169.12 | 2023-2025 | Qutenza |
| Amylyx Pharmaceuticals, INC. | $167.69 | 2023 | Relyvrio |
| Xeris Pharmaceuticals, INC. | $148.47 | 2021-2023 | Gvoke Hypopen |
| Currax Pharmaceuticals LLC | $144.23 | 2021-2022 | |
| Radius Health, INC. | $138.65 | 2022-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $129.73 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Grt US Holding, INC. | $89.51 | 2021-2022 | |
| Cequr Corporation | $86.56 | 2023-2025 | Cequr Simplicity |
| Sequel Med Tech, LLC | $84.77 | 2025 | Twiist |
| Biohaven Pharmaceutical Holding Company LTD. | $81.33 | 2022 | |
| Ibsa Pharma INC. | $79.00 | 2022-2025 | Tirosint, Licart, Tirosint |
| Otsuka America Pharmaceutical, INC. | $74.85 | 2021 | |
| Neurocrine Biosciences, INC. | $72.00 | 2023-2025 | Ingrezza, Ongentys |
| Janssen Pharmaceuticals, INC | $69.37 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.02 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $67.26 | 2021-2023 | Austedo Xr |
| Vistapharm, INC. | $66.64 | 2021 | |
| Alexion Pharmaceuticals, INC. | $61.45 | 2021-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $52.52 | 2025 | Yorvipath |
| Acerus Pharmaceuticals Corporation | $49.40 | 2021 | |
| Janssen Biotech, INC. | $44.34 | 2023 | Simponi Aria, Remicade, Simponi |
| Echosens North America, INC. | $40.39 | 2025 | Fibroscan |
| Pfizer INC. | $33.50 | 2022-2023 | |
| Lifescan, INC. | $30.17 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $30.11 | 2021 | |
| Halozyme INC | $29.56 | 2023 | |
| Aurinia Pharma U.S., INC. | $28.16 | 2023 | Lupkynis |
| Ge Healthcare | $24.91 | 2023 | |
| Mylan Specialty L.P. | $24.53 | 2021 | |
| Ucb, INC. | $23.12 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $21.63 | 2021 | |
| Abbvie INC. | $21.19 | 2023 | |
| Paratek Pharmaceuticals, INC. | $20.79 | 2021 | |
| Soleno Therapeutics, INC. | $19.17 | 2025 | Vykat Xr |
| Inspire Medical Systems, INC. | $18.79 | 2025 | Inspire |
| Lundbeck LLC | $17.01 | 2021 | |
| Ascensia Diabetes Care US INC. | $16.55 | 2025 | |
| Endo Pharmaceuticals INC. | $15.71 | 2022 | |
| Indivior INC. | $13.00 | 2021 | |
| Bigfoot Biomedical INC | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.